Medical treatment in head and neck cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; RALTITREXED; TOPOTECAN; UFT;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; INFECTION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RADIOTHERAPY, ADJUVANT;

EID: 21344466795     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi735     Document Type: Article

References (58)

1. Fortin A, Couture C, Doucet R et al. Does histologic grade have a role in the management of head and neck cancer? J Clin Oncol 2001; 19: 4107-4116.
2. León X, Quer M, Orús C, del Prado Venegas M. Can cure be achieved in patients with head and neck carcinomas? The problem of second neoplasm. Expert Rev Anticancer Ther 2001; 1: 125-133.
3. Al-Sarraf M, Hussein M. Head and neck cancer: present status and future prospects of adjuvant chemotherapy. Cancer Invest 1995; 13: 41-53.
4. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
5. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
6. Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-526.
7. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71: 83-91.
8. El Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14: 838-847.
9. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck cancer squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949-955.
10. Browman GP, Hodson DI, Mackenzie RJ et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer. A systematic review of the published literature with subgroup analysis. Head Neck 2001; 23: 579-589.
11. Hong WK, Bromer R. Chemotherapy in head and neck cancer. N Engl J Med 1983; 308: 75-79.
12. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol 1988; 15: 70-85.
13. Schrijvers D, Vermorken JB. Update on the taxoids and other new agents in head and neck cancer therapy. Curr Opin Oncol 1998; 10: 233-241.
14. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000; 5: 199-208.
15. Murphy BA, Cmelak A, Burkey B et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology (Huntingt) 2001; 15: 47-52.
16. Vermorken JB, Catimel G, De Mulder P et al. Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999; 18: 395a (Abstr).
17. Guardiola E, Peyrade F, Chaigneau L et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40: 2071-2076.
18. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology, 6th edition. Philadelphia: Lippincott-Raven Publishers 2001; 797-860.
19. Kim KB, Khuri FR, Shin DM. Recent advances in the management of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2001; 1: 99-110.
20. Murphy B, Li Y, Cella D et al. Phase III study comparing cisplatin and 5-fluorouracil versus cisplatin and paclitaxel in metastatic/recurrent head & neck cancer. Proc Am Soc Clin Oncol 2001; 20: 224a (Abstr).
21. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship, in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101: 2222-2229.
22. Cohen EEW. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol 2004; 31: 775-768.
23. Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 2001; 6: 517-537.
24. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
25. Kane MA, Cohen E, List M et al. Phase II study of 250mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2004; 22 (Suppl): 509 (Abstr).
26. Herbst RS, Kim ES, Harari PM. IMC-225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Ther 2001; 1: 719-732.
27. Baselga JM, Trigo J, Bourhis J et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002; 21: 226a (Abstr).
28. Kies MS, Arguette MA, Narbell L et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 232a (Abstr).
29. Trigo J, Hitt R, Koralewski P et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol 2004; 22 (Suppl): 488s (Abstr).
30. Burtness BA, Li Y, Flood W et al. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 2002; 21: 226a (Abstr).
31. Humblet Y, Vega-Villegas E, Mesia R et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patient (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2004; 22 (Suppl): 491.
32. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the Head and Neck Contracts Program. Cancer 1987; 60: 301-311.
33. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-272.
34. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899.
35. Laramore GE, Scott CB, Al-Sarraf M et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup study 0034. Int J Radiat Oncol Biol Phys 1992; 23: 705-713.
36. Harari PM, Cleary JF, Hartig GK. Evolving patterns of practice regarding the use of chemoradiation for advanced head and neck cancer patients. Proc Am Soc Clin Oncol 2001; 20: 226a.
37. Colevas AD, Norris CM, Tishler RB et al. Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17: 3503-3511.
38. Posner MR, Glisson B, Frenette G et al. Mulitcenter phase I-II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19: 1096-1104.
39. Hitt R, Paz-Ares L, Brandariz A et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 2002; 13: 1665-1673.
40. Hitt R, Lopez-Pousa M, Ropdriguez M et al. Phase III study comparing cisplatin (P) and 5-fluorouracil (F) versus P, F and paclitaxel as induction therapy in locally advanced head and neck cancer. Proc Am Soc Clin Oncol 2003; 22: 496 (Abstr).
41. Vermorken JB, Remenar E, van Herpen J et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trials of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 2004; 22 (Suppl): 490s (Abstr).
42. Benasso M, Sanguinetti G, D'Amico M et al. Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma. Br J Cancer 2000; 83: 1437-1442.
43. Rischin D, Corry J, Smith J et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002; 20: 1845-1852.
44. Wolf GT, Hong WK, Fisher S et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Departments of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
45. Wolf GT. Commentary: phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concurrent chemotherapy and radiotherapy versus radiotherapy-Intergroup trial R91-11. J Clin Oncol 2001; 18: 28-31.
46. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
47. Merlano M, Benasso M, Corvo R et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996; 88: 583-589.
48. Bourhis J, Armand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head and Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004; 22 (Suppl): 489 (Abstr).
49. Brizel DM. Management of Advanced Head and Neck Cancer with Radiotherapy and Concurrent Chemotherapy: Improvements in Efficacy and Toxicity Management Strategies. ASCO Educational Book 2000; Baltimore, MD: Lippincott Williams & Wilkins; 219-225.
50. Bachaud JM, Cohen JE, Alzieu C et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996; 36: 999-1004.
51. Bernier J, Domenge C, Ozsahin M et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1945-1952.
52. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiochemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
53. Busto G, Corvo R, Ricci I et al. New chemoradiotherapy combinations in head and neck cancer. Expert Rev Anticancer Ther 2001; 1: 111-115.
54. Domenge C, Marandas P, Vignoud J et al. Post-surgical adjuvant chemotherapy in extracapsular spread invaded lymph node (N +R+) of epidermoid carcinoma of the head and neck. A randomized multicentric trial. Second International Conference on Head and Neck Cancer, Boston, 1988. 74: (Abstr).
55. Tsukuda M, Ogasawara H, Kaneko S et al. A prospective randomized trial of adjuvant chemotherapy with UFT for head and neck carcinoma. Head and Neck UFT study group. Gan To Kagaku Ryoho 1994; 21: 1169-1177.
56. Ervin TJ, Clark JR, Weichselbaum RR et al. An analysis of induction and adjuvant chemotherapy in multidisciplinary treatment of squamous cell carcinoma of the head and neck. J Clin Oncol 1987; 5: 10-20.
57. Al-Sarraf M, LeBlanc M, Shanker PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
58. Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.